Brian Steingo

1.6k total citations
12 papers, 161 citations indexed

About

Brian Steingo is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Brian Steingo has authored 12 papers receiving a total of 161 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 4 papers in Neurology and 4 papers in Rheumatology. Recurrent topics in Brian Steingo's work include Multiple Sclerosis Research Studies (8 papers), Peripheral Neuropathies and Disorders (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Brian Steingo is often cited by papers focused on Multiple Sclerosis Research Studies (8 papers), Peripheral Neuropathies and Disorders (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Brian Steingo collaborates with scholars based in United States, United Kingdom and Germany. Brian Steingo's co-authors include Kottil Rammohan, David J. Adams, Sven G. Meuth, Melissa Ortega, Carlos Parra‐Herran, Ann Bass, Keith R. Edwards, Neetu Agashivala, Regina Berkovich and Nadia Daizadeh and has published in prestigious journals such as Neurology, Journal of Neuroimmunology and Journal of Neurology.

In The Last Decade

Brian Steingo

9 papers receiving 160 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Steingo United States 7 122 62 39 36 27 12 161
Marcos Papais Alvarenga Brazil 9 163 1.3× 71 1.1× 52 1.3× 49 1.4× 42 1.6× 14 198
James Hrastelj United Kingdom 5 219 1.8× 85 1.4× 59 1.5× 56 1.6× 32 1.2× 9 263
Gerardo Iuliano Italy 8 229 1.9× 110 1.8× 68 1.7× 71 2.0× 51 1.9× 13 285
K. Baker United Kingdom 3 184 1.5× 99 1.6× 44 1.1× 63 1.8× 64 2.4× 3 238
Enrique Gómez‐Figueroa Mexico 9 75 0.6× 97 1.6× 16 0.4× 21 0.6× 14 0.5× 28 180
Elżbieta Jasińska Poland 6 106 0.9× 36 0.6× 49 1.3× 30 0.8× 21 0.8× 12 176
I. Kupfer France 6 37 0.3× 16 0.3× 14 0.4× 21 0.6× 35 1.3× 11 153
Mark Cascione United States 9 129 1.1× 49 0.8× 37 0.9× 33 0.9× 21 0.8× 17 169
E. Poszepczynska-Guigné France 8 197 1.6× 32 0.5× 41 1.1× 98 2.7× 85 3.1× 11 368
Tereza Hrnčiarová Czechia 5 34 0.3× 20 0.3× 38 1.0× 12 0.3× 36 1.3× 8 122

Countries citing papers authored by Brian Steingo

Since Specialization
Citations

This map shows the geographic impact of Brian Steingo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Steingo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Steingo more than expected).

Fields of papers citing papers by Brian Steingo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Steingo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Steingo. The network helps show where Brian Steingo may publish in the future.

Co-authorship network of co-authors of Brian Steingo

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Steingo. A scholar is included among the top collaborators of Brian Steingo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Steingo. Brian Steingo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Abboud, Hesham, Brian Steingo, Diana Vargas, et al.. (2025). Satralizumab treatment in patients with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series. Journal of Neuroimmunology. 403. 578585–578585.
2.
3.
Steingo, Brian, Yaser Al Malik, Ann Bass, et al.. (2020). Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. Journal of Neurology. 267(11). 3343–3353. 41 indexed citations
4.
Wijmeersch, Bart Van, B. Singer, Aaron Boster, et al.. (2019). Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. Multiple Sclerosis Journal. 26(13). 1719–1728. 16 indexed citations
5.
Amezcua, Lilyana, Regina Berkovich, Ángel Chinea, et al.. (2019). Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study). Neurology and Therapy. 8(2). 367–381. 8 indexed citations
6.
Cuker, Adam, Ann Bass, Čongor Nadj, et al.. (2019). Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. Multiple Sclerosis Journal. 26(1). 48–56. 34 indexed citations
7.
Oreja‐Guevara, Celia, Raed Alroughani, David Brassat, et al.. (2017). Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study). Queensland's institutional digital repository (The University of Queensland). 1 indexed citations
8.
Kantor, Daniel & Brian Steingo. (2017). Pneumonitis as an early complication of alemtuzumab treatment (P5.406). Neurology. 88(16_supplement).
9.
10.
11.
Ortega, Melissa, et al.. (2012). CLIPPERS complicating multiple sclerosis causing concerns of CNS lymphoma. Neurology. 79(7). 715–716. 22 indexed citations
12.
Saffer, D, et al.. (1974). Huntington's disease in a Coloured family.. PubMed. 48(58). 2399–402. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marcos Papais Alvarenga Breakdown of academic impact, for papers by James Hrastelj Breakdown of academic impact, for papers by Gerardo Iuliano Breakdown of academic impact, for papers by K. Baker Breakdown of academic impact, for papers by Enrique Gómez‐Figueroa Breakdown of academic impact, for papers by Elżbieta Jasińska Breakdown of academic impact, for papers by I. Kupfer Breakdown of academic impact, for papers by Mark Cascione Breakdown of academic impact, for papers by E. Poszepczynska-Guigné Breakdown of academic impact, for papers by Tereza Hrnčiarová
Rankless by CCL
2026